← All reports

Eli Lilly and Company's acquisition of Kelonia Therapeutics is aimed at advancing in vivo CAR-T cell therapies.

HealthcareTechnologyMergersAcquisitionsApr 20, 2026score 0.172 posts · 0 replies across 1 instances
The thread discusses Eli Lilly's acquisition of Kelonia Therapeutics to develop in vivo CAR-T cell therapies, highlighting a significant move in the biotechnology sector. This acquisition is seen as a strategic step towards advancing innovative medical treatments, which could have implications for healthcare and pharmaceutical industries.

Claims

Eli Lilly and Company's acquisition of Kelonia Therapeutics is aimed at advancing in vivo CAR-T cell therapies.
Parent: BiotechnologyEntity: Eli Lilly and CompanySub-entity: Acquisition of Kelonia TherapeuticsImpact: positiveDate: Apr 20, 2026Target: Eli Lilly and Company's acquisition of Kelonia Therapeutics

Source posts

@[email protected]
https://www.europesays.com/news/18381/ Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies #Headlines #News #TopStories
0 boosts · 0 favs · 0 replies · Apr 20, 2026
#topstories#news#headlines
@[email protected]
https://www.europesays.com/ie/444786/ Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies #Acquisitions #Biotechnology #Éire #EliLillyAndCompany #Health #HealthCare #HealthCare&Hospitals #Healthcare #IE #Ireland #MedicalPharmaceuticals #MergersAndTakeovers #pharmaceuticals
0 boosts · 0 favs · 0 replies · Apr 20, 2026
#pharmaceuticals#mergersandtakeovers#medicalpharmaceuticals#ireland#ie#healthcare
@[email protected]
https://www.europesays.com/uk/906980/ Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies #EliLillyAndCompany #Health #Healthcare #UK #UnitedKingdom
0 boosts · 0 favs · 0 replies · Apr 20, 2026
#unitedkingdom#uk#healthcare#health#elilillyandcompany